14 completed. 10 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Submental Fat: new trials by email Literature Review of Submental Fat trials Research Report on Submental Fat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study That Will Test a Second Treatment Session of RZL-012. RZL-012 - Submental Fat | Phase 2 | Completed | Raziel Therapeutics Ltd. | 15 | 2023-05-29 | 2023-11-18 |
| Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol - Submental Fat | Phase 1 / Phase 2 | Completed | Raziel Therapeutics Ltd. | 48 | 2022-09-25 | 2024-01-30 |
| Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects Polyene Phosphatidylcholine - Healthy Subjects, Submental Fat | Phase 1 | Completed | AMIpharm Co., Ltd. | 26 | 2022-08-10 | 2026-01-22 |
| An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects. RZL-012 - Submental Fat | Phase 1 / Phase 2 | Completed | Raziel Therapeutics Ltd. | 20 | 2022-07-29 | 2023-12-19 |
| Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat MT921, Placebo - Submental Fat | Phase 3 | Completed | Medy-Tox | 240 | 2021-12-24 | 2023-02-23 |
| A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat 10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection - Submental Fat | Phase 2 | Completed | 10xBio, LLC | 51 | 2021-10-19 | 2025-06-29 |
| Efficacy and Safety of RZL-012 on Submental Fat Reduction RZL-012, Placebo - Submental Fat | Phase 2 | Completed | Raziel Therapeutics Ltd. | 151 | 2021-06-15 | 2023-09-28 |
| A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. RZL-012, Placebo - Submental Fat | Phase 2 | Completed | Raziel Therapeutics Ltd. | 28 | 2020-02-25 | 2023-11-18 |
| A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin") 10XB-101 Solution for Injection - Submental Fat | Phase 2 | Completed | 10xBio, LLC | 15 | 2019-10-10 | 2024-04-10 |
| A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat MT921, Placebo - Submental Fat | Phase 2 | Completed | Medy-Tox | 176 | 2019-09-10 | 2020-07-29 |
| Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat Normal saline, DWJ211 - Submental Fat | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 148 | 2019-05-15 | 2024-04-04 |
| Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat LIPO-202, Placebo for LIPO-202 - Submental Fat | Phase 2 | Completed | Neothetics, Inc | 162 | 2016-12-22 | 2017-10-20 |
| Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 ATX-101, Placebo - Submental Fat, Healthy | Phase 3 | Completed | Kythera Biopharmaceuticals | 224 | 2013-12-01 | 2020-02-17 |
| Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Placebo, ATX-101 (1 mg/cm^2), ATX-101 (2 mg/cm^2) - Submental Fat, Healthy | Phase 2 | Completed | Kythera Biopharmaceuticals | 205 | 2009-02-01 | 2020-02-17 |
RZL-012 (5) · Injections (3) · Polidocanol (1) · Saline Solution (1) · Salmeterol Xinafoate (1) · polyene phosphatidylcholine (1)
Raziel Therapeutics Ltd. (5) · 10xBio, LLC (2) · Kythera Biopharmaceuticals (2) · Medy-Tox (2) · AMIpharm Co., Ltd. (1) · Daewoong Pharmaceutical Co. LTD. (1) · Neothetics, Inc (1)
United States (10) · South Korea (4) · Canada (2) · Australia (1) · United Kingdom (1)
Frederick Beddingfield, III, MD, PhD (2) · Daniel Piacquadio, MD (1) · Jae Yong Chung, M.D.,Ph.D (1) · John Dobak, MD (1) · Raceli Gueta, PhD (1)